PMV PHARMACEUTICALS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
PMV PHARMACEUTICALS, INC. (PMVP) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 15.82 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-14
- PMV PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 15.66M shares, a 21.62% increase year-over-year.
- PMV PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 12.87M shares, a 26.05% increase year-over-year.
- PMV PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 10.21M shares, a 78.15% increase year-over-year.
- PMV PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 5.73M shares, a 8.94% increase year-over-year.
- PMV PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 12.00M shares, a 25.42% increase from fiscal 2024.
- PMV PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 9.57M shares, a 32.63% increase from fiscal 2023.
- PMV PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 7.21M shares, a 25.44% increase from fiscal 2022.
- PMV PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 5.75M shares, a 33.93% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | 15.82M shares 10-Q · filed 2026-08-14 | |||||
| 2026-03-31 | 15.66M shares 10-Q · filed 2026-05-12 | |||||
| 2025-12-31 | 12.00M shares 10-K · filed 2026-03-06 | |||||
| 2025-09-30 | 12.24M shares 10-Q · filed 2025-11-12 | |||||
| 2025-06-30 | 12.22M shares 10-Q · filed 2026-08-14 | |||||
| 2025-03-31 | 12.87M shares 10-Q · filed 2026-05-12 | |||||
| 2024-12-31 | 9.57M shares 10-K · filed 2026-03-06 | |||||
| 2024-09-30 | 9.64M shares 10-Q · filed 2025-11-12 | |||||
| 2024-06-30 | 9.90M shares 10-Q · filed 2025-08-07 | |||||
| 2024-03-31 | 10.21M shares 10-Q · filed 2025-05-09 | |||||
| 2023-12-31 | 7.21M shares 10-K · filed 2026-03-06 | |||||
| 2023-09-30 | 7.49M shares 10-Q · filed 2024-11-07 | |||||
| 2023-06-30 | 7.56M shares 10-Q · filed 2024-08-08 | |||||
| 2023-03-31 | 5.73M shares 10-Q · filed 2024-05-09 | |||||
| 2022-12-31 | 5.75M shares 10-K · filed 2025-03-03 | |||||
| 2022-09-30 | 5.71M shares 10-Q · filed 2023-11-09 | 6.46M shares 10-Q · filed 2022-11-08 | ||||
| 2022-06-30 | 5.38M shares 10-Q · filed 2023-08-09 | |||||
| 2022-03-31 | 5.26M shares 10-Q · filed 2023-05-10 | |||||
| 2021-12-31 | 4.29M shares 10-K · filed 2024-02-29 | 4.25M shares 10-K · filed 2022-03-01 | ||||
| 2021-09-30 | 5.04M shares 10-Q · filed 2022-11-08 | |||||
| 2020-12-31 | 4.09M shares 10-K · filed 2022-03-01 | |||||
| 2020-09-30 | 4.06M shares 10-Q · filed 2020-11-13 | |||||
| 2019-12-31 | 25.64M shares 10-K · filed 2022-03-01 | |||||
| 2019-09-30 | 20.20M shares 10-Q · filed 2020-11-13 | |||||
| 2018-12-31 | 20.09M shares 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |